Quote:But since we sit at 11 cents/share, and since we were at about 30 cents a share just before I bought in back in March 2020, I have to believe there is a deliberate effort to suppress our SP. There is no other molecule like ours, nothing so safe and with so much potential (at least none that I've heard of), so the ONLY thing that makes 11 cents/share possible is deliberate suppression.
Large biopharmas want us to crash and burn, and "they" had enough influence with the FDA to keep a molecule with an absolutely stellar safety profile on a safety hold for 2 years.
If BP is trying to force us to crash and burn they're certainly going about it the wrong way. We have money to move forward with the mssCRC trial and funding for the Alzheimer's pilot study. Results from those or possibly some other catalyst will certainly drive the share price higher giving an opportunity to further the next trials. If BP had so much influence the safety hold would have never been lifted.
For those who think that BP buying out Cytodyn is just around the corner. Don't you think an 11 cent share price would be an opportune time. They could be magnanimous and offer 50 cents a share but none has.
Waiting is a drag, but wait we must. Nothing ever goes fast in biopharma land. The ROI is worth the wait, especially for those continuing to buy.
25
